CareDx heads into its August 4 earnings report carrying the imprint of a dramatic short squeeze — and a CEO who sold into it.
The most striking development in the run-up is how aggressively short sellers have retreated. Short interest collapsed 30% in a single week, dropping from roughly 8.7 million shares to just under 5.5 million, and now represents 10.7% of the free float — still elevated in absolute terms, but falling fast. That covering wave likely helped fuel a 53% rally in the stock over the past month, with a further 15% surge on Thursday alone. The lending market tells the same story: availability has loosened dramatically to 2,348% — meaning more than 23 shares are available to borrow for every one currently lent out — a far cry from the tighter conditions seen in early July when availability was below 650%. Borrow costs remain negligible at 0.37%. The short score has also dropped meaningfully, from above 62 in mid-July to around 54 today, reflecting that the technical pressure from short positioning has eased.
Options positioning complicates that picture. Despite the covering, the put/call ratio remains very elevated at 3.72 — well above its 20-day average of 2.38 — suggesting that traders have been layering on downside protection even as the stock rips higher. The PCR has been running near its 52-week high for most of July, which means the options market is carrying a defensive tilt into the print that stands in contrast to the short covering in the stock-lending market.
The analyst community is divided and the stock has now moved above most targets. BTIG, the most consistent bull, raised its target to $45 earlier in July and maintains a Buy. HC Wainwright reiterated Neutral on Friday with a $46 target — a level the stock at $43.71 is now approaching. Bears point to reimbursement risk on AlloSure and AlloMap, the core revenue drivers, plus uncertainty around newer products like AlloHeme. Bulls counter with strong testing volume trends, improving cash flow metrics, and the company's positioning as the dominant player in transplant surveillance. The valuation has stretched: the PE multiple has expanded roughly 6 points over the past 30 days and the P/B ratio has climbed by over 1.3x. With most analyst targets now clustered around or below the current price, the stock has moved into territory where the earnings print must carry the weight.
Insider activity adds one final layer of caution. The CEO sold shares at prices between $29 and $39 across multiple transactions in June and July — well below where the stock now trades — behavior consistent with planned disposals but notable in its scale ahead of a major catalyst. Tuesday's report is therefore less a test of whether CareDx is growing and more a test of whether the reimbursement trajectory and volume data can justify a stock that has already priced in a great deal of good news.
See the live data behind this article on ORTEX.
Open CDNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
